Notably, the clinical responses across all treatment arms (AUC C-peptide from MMTT, insulin consumption, HbA1c, and episodes of hypoglycemia) were within the expected range when compared with a previously published model [31]. This evidence concerns the gene INS and Hypoglycemia.